Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$21.18 -3.5%	$24.53	$21.16 ▼ $53.96	$998.43M	0.72	496,969 shs	504,333 shs
NTLA Intellia Therapeutics	$11.48 -3.9%	$9.06	$5.90 ▼ $28.18	$1.19B	2.21	3.04 million shs	3.45 million shs
TKNO Alpha Teknova	$4.40 -2.0%	$5.73	$1.23 ▼ $10.37	$235.14M	0.33	425,998 shs	507,497 shs
WVE WAVE Life Sciences	$7.71 -1.7%	$6.71	$5.04 ▼ $16.74	$1.20B	-1.01	1.30 million shs	1.45 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	+1.34%	-3.98%	-14.99%	-6.60%	-43.28%
NTLA Intellia Therapeutics	+3.64%	+16.59%	+43.80%	+62.36%	-53.66%
TKNO Alpha Teknova	-6.65%	-10.02%	-18.07%	-22.98%	+250.78%
WVE WAVE Life Sciences	+1.82%	+11.05%	+12.81%	+24.84%	+39.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	4.3162 of 5 stars	3.1	2.0	3.7	1.9	4.2	1.3
NTLA Intellia Therapeutics	4.3354 of 5 stars	4.3	1.0	4.7	1.4	2.5	0.6
TKNO Alpha Teknova	2.0356 of 5 stars	3.5	1.0	0.0	2.2	1.7	0.6
WVE WAVE Life Sciences	4.4411 of 5 stars	3.5	2.0	4.8	1.9	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.25	Hold	$32.33	52.66% Upside
NTLA Intellia Therapeutics	2.65	Moderate Buy	$33.37	190.67% Upside
TKNO Alpha Teknova	3.00	Buy	$12.00	172.73% Upside
WVE WAVE Life Sciences	2.92	Moderate Buy	$20.50	165.89% Upside

Current Analyst Ratings Breakdown

Latest TKNO, NTLA, AMPH, and WVE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	WVE WAVE Life Sciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$18.00
6/16/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
6/16/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/11/2025	WVE WAVE Life Sciences	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$14.00
6/3/2025	NTLA Intellia Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $54.00
5/29/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00 ➝ $7.00
5/29/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/20/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/19/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00 ➝ $10.00
5/12/2025	AMPH Amphastar Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$45.00 ➝ $30.00
5/12/2025	NTLA Intellia Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $45.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$731.97M	1.36	$4.89 per share	4.33	$15.23 per share	1.39
NTLA Intellia Therapeutics	$57.88M	20.54	N/A	N/A	$8.56 per share	1.34
TKNO Alpha Teknova	$38.25M	6.15	N/A	N/A	$1.55 per share	2.84
WVE WAVE Life Sciences	$108.30M	11.07	N/A	N/A	$1.37 per share	5.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$159.52M	$2.76	7.67	6.44	5.64	19.38%	22.20%	10.40%	8/6/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$5.23	N/A	N/A	N/A	-1,154.10%	-56.06%	-44.25%	8/14/2025 (Estimated)
TKNO Alpha Teknova	-$26.75M	-$0.48	N/A	N/A	N/A	-60.90%	-28.48%	-19.73%	8/12/2025 (Estimated)
WVE WAVE Life Sciences	-$97.01M	-$0.84	N/A	N/A	N/A	N/A	-86.49%	-37.20%	8/14/2025 (Estimated)

Latest TKNO, NTLA, AMPH, and WVE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	AMPH Amphastar Pharmaceuticals	$0.71	N/A	N/A	N/A	$173.42 million	N/A
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/8/2025	Q1 2025	TKNO Alpha Teknova	-$0.11	-$0.09	+$0.02	-$0.09	$9.41 million	$9.60 million
5/8/2025	Q1 2025	WVE WAVE Life Sciences	-$0.27	-$0.29	-$0.02	-$0.29	$11.65 million	$9.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
TKNO Alpha Teknova	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.80	2.95	2.02
NTLA Intellia Therapeutics	N/A	4.90	4.90
TKNO Alpha Teknova	0.17	5.64	4.71
WVE WAVE Life Sciences	N/A	2.95	2.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
NTLA Intellia Therapeutics	88.77%
TKNO Alpha Teknova	13.81%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.10%
NTLA Intellia Therapeutics	3.10%
TKNO Alpha Teknova	12.50%
WVE WAVE Life Sciences	23.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	2,028	47.14 million	34.36 million	Optionable
NTLA Intellia Therapeutics	600	103.58 million	100.37 million	Optionable
TKNO Alpha Teknova	240	53.44 million	46.76 million	Not Optionable
WVE WAVE Life Sciences	240	155.56 million	118.26 million	Optionable

TKNO, NTLA, AMPH, and WVE Headlines

Recent News About These Companies

WAVE Life Sciences (NASDAQ:WVE) Shares Down 6.5% - What's Next?

1 hour ago | marketbeat.com

Leerink Partners Reiterates a Buy Rating on Wave Life Sciences (WVE), Keeps the PT at $24

July 11, 2025 | msn.com

NASDAQ:WVE Financials | Wave Life Sciences Ltd - Investing.com

July 11, 2025 | investing.com

WAVE Life Sciences (NASDAQ:WVE) Trading Up 6.8% - Should You Buy?

July 9, 2025 | marketbeat.com

Brokerages Set WAVE Life Sciences Ltd. (NASDAQ:WVE) PT at $20.50

July 9, 2025 | americanbankingnews.com

WAVE Life Sciences Ltd. Company & People | WVE | Barron's

July 7, 2025 | barrons.com

Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 Months

July 7, 2025 | seekingalpha.com

Wave Life Sciences: Speculative, But Promising

July 7, 2025 | seekingalpha.com

Wave Life Sciences Ltd. (WVE) - Yahoo Finance

July 6, 2025 | finance.yahoo.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Brokerages

July 6, 2025 | marketbeat.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 6, 2025 | marketbeat.com

Moody Aldrich Partners LLC Increases Holdings in WAVE Life Sciences Ltd. (NASDAQ:WVE)

July 4, 2025 | marketbeat.com

H.C. Wainwright Reaffirms Buy Rating on Wave Life Sciences After ADA Data Release

July 3, 2025 | msn.com

Where WAVE Life Sciences Stands With Analysts

June 23, 2025 | benzinga.com

WAVE Life Sciences (NASDAQ:WVE) Receives "Outperform" Rating from Wedbush

June 23, 2025 | marketbeat.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA ...

June 22, 2025 | manilatimes.netM

Wave Life Sciences Presents Promising Preclinical Data for WVE-007, a Novel siRNA Obesity Treatment at American Diabetes Association Meeting

June 22, 2025 | nasdaq.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ...

June 20, 2025 | finance.yahoo.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

June 20, 2025 | globenewswire.com

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?

June 20, 2025 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Shares Cross Below 50-Day Moving Average - Time to Sell?

June 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
By Brian O'Connell | July 15, 2025
View Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook

TKNO, NTLA, AMPH, and WVE Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$21.18 -0.77 (-3.51%)

Closing price 04:00 PM Eastern

Extended Trading

$21.25 +0.07 (+0.33%)

As of 04:24 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Intellia Therapeutics NASDAQ:NTLA

$11.48 -0.47 (-3.93%)

Closing price 04:00 PM Eastern

Extended Trading

$11.54 +0.06 (+0.52%)

As of 04:38 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Alpha Teknova NASDAQ:TKNO

$4.40 -0.09 (-2.00%)

Closing price 04:00 PM Eastern

Extended Trading

$4.40 0.00 (0.00%)

As of 04:31 PM Eastern

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

WAVE Life Sciences NASDAQ:WVE

$7.71 -0.13 (-1.66%)

Closing price 04:00 PM Eastern

Extended Trading

$7.72 +0.00 (+0.06%)

As of 04:24 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time